CONTROL BIONICS LIMITED (CBL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CBL - CONTROL BIONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Technology Hardware & Equipment
Debt/EBITDA: -0.02
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.046

27 Mar
2024

-0.001

OPEN

$0.05

-2.13%

HIGH

$0.05

64,028

LOW

$0.05

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CBL: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A N/A xxx
DPS (cps) xxx N/A N/A xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 08/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 20192020202120222023
EPS Basic xxxxxxxxxxxx-5.6
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx5.6 M
Book Value Per Share xxxxxxxxxxxx7.1
Net Operating Cash Flow xxxxxxxxxxxx-4.5 M
Net Profit Margin xxxxxxxxxxxx-99.80 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20192020202120222023
Return on Capital Employed xxxxxxxxxxxx-59.05 %
Return on Invested Capital xxxxxxxxxxxx-58.67 %
Return on Assets xxxxxxxxxxxx-50.89 %
Return on Equity xxxxxxxxxxxx-59.05 %
Return on Total Capital xxxxxxxxxxxx-62.40 %
Free Cash Flow ex dividends xxxxxxxxxxxx-4.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20192020202120222023
Short-Term Debt xxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxx-
Total Debt xxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx1 M
Price To Book Value xxxxxxxxxxxx1.10

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20192020202120222023
Capex xxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxx8.11 %
Cost of Goods Sold xxxxxxxxxxxx8 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx4 M
Research & Development xxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

05/03/2024

-1

No Rating

-

A first half net loss of -$2.2m from Control Bionics in the first half was an improvement year-on-year, points out Morgans. The company reported revenue of $3.0m and an earnings loss of -$1.8m.

The company is anticipating growth in the second half, and, with a cash balance of $1.3m and no debt as of the end of the first half, Morgans considers there to be sufficient cash to fund operations through to the end of the year.

CBL STOCK CHART